Ensign Peak Advisors’s SOPHiA GENETICS SOPH Stock Holding History
Bought
Maintained
Sold
Other funds holding SOPH
ACM
Ensign Peak Advisors's SOPH Position: Q3 2026 in Review
Ensign Peak Advisors increased its SOPHiA GENETICS (SOPH) stake by 53% in Q3 2026, buying an estimated $1.71M and bringing the position to 681,812 shares worth $5.71M. The position accounts for 0.01% of the portfolio, ranked #538.
Ensign Peak Advisors first reported a position in SOPH in Q2 2025 and has held it in 6 quarters since. 52 funds tracked by Wall St. Rank hold SOPH as of Q3 2026.
- Ensign Peak Advisors held 681,812 shares of SOPHiA GENETICS worth $5.71M as of Q3 2026.
- Ensign Peak Advisors bought 237,158 SOPHiA GENETICS shares in Q3 2026, an estimated $1.71M.
- SOPHiA GENETICS made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #538 holding.
- Ensign Peak Advisors first reported a position in SOPHiA GENETICS in Q2 2025 and has held it in 6 quarters since.
- 52 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.